ライフサイエンスコーパス: tuberculosis

1 curable tuberculosis (totally drug-resistant tuberculosis).

2 QR 75-271]), 163 (14%) had culture-confirmed tuberculosis.

3 ependent of RpsA and trans-translation in M. tuberculosis.

4 d by screening 42 targets from Mycobacterium tuberculosis.

5 no symptoms, of whom 41 (3%) had coprevalent tuberculosis.

6 ontrol subjects, and patients with pulmonary tuberculosis.

7 ed and (6) then has the potential to develop tuberculosis.

8 .3%) were culture-positive for Mycobacterium tuberculosis.

9 rculosis disease among HHCs of patients with tuberculosis.

10 s (69%) had never received treatment for MDR tuberculosis.

11 strategy for host-directed therapies against tuberculosis.

12 NA polymerase, a validated drug target in M. tuberculosis.

13 ator of ongoing community transmission of M. tuberculosis.

14 on to treat leprosy and multi-drug-resistant tuberculosis.

15 y human macrophages exposed to Mycobacterium tuberculosis.

16 Of 59 patients with HIV-tuberculosis, 16 (27%) died after a median of 12 days (i

17 been proposed in which (1) a source case of tuberculosis (2) generates infectious particles (3) that

18 M. tuberculosis 6-kDa early secretory antigenic target (ESA

19 One hundred patients with pulmonary tuberculosis (65% human immunodeficiency virus coinfecte

20 e emergence of new diagnostics and drugs for tuberculosis, a disease that kills over 1.8 million peop

21 V infection was associated with increased M. tuberculosis Ag-induced CD4 T cell death ex vivo, indica

22 It also predicted the percentage of XDR tuberculosis among incident MDR tuberculosis to increase

23 ) of 7982 patients with tuberculosis had MDR tuberculosis and 324 (88%) of these had isolates availab

24 tuberculosis was found to have disseminated tuberculosis and a clinically unsuspected partial thromb

25 the rate of death from infection (including tuberculosis and cryptococcus) shortly after the initiat

26 information on the participants' history of tuberculosis and HIV infection, hospitalizations, and so

27 oach using data from 34,446 respondents to a tuberculosis and human immunodeficiency virus (HIV) prev

28 been associated with increased incidence of tuberculosis and infections with non-tuberculous mycobac

29 immune signatures that differ between active tuberculosis and LTBI to distinguish recently from remot

30 We too find ESX-1 of M. tuberculosis and M. marinum lyses host cell membranes.

31 mycobacterial hosts including Mycobacterium tuberculosis and Mycobacterium smegmatis, encompass subs

32 l subset is protective against Mycobacterium tuberculosis and other infections.

33 Mycobacterium tuberculosis and related Corynebacterineae synthesize a

34 rt Ultra with that of Xpert for detection of tuberculosis and rifampicin resistance.

35 c interactions occurring in the lungs for M. tuberculosis and their impact on infection and persisten

36 c formulations for other diseases, including tuberculosis and viral hepatitis.

37 ommunicable diseases (excluding HIV/AIDS and tuberculosis) and maternal, perinatal, and nutritional c

38 for latent tuberculosis infection, pulmonary tuberculosis, and extrapulmonary tuberculosis are provid

39 w and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child health.

40 ed ART-treated individuals in response to M. tuberculosis antigen stimulation.

41 such as Prevotella in the lung, and with M. tuberculosis antigen-induced Tregs.

42 ole proteome screen identified Mycobacterium tuberculosis antigens associated with serological respon

43 Samples where many M. tuberculosis aptamers produced high signals were rare ex

44 The current drug regimens for treating tuberculosis are lengthy and onerous, and hence complica

45 city of variation means that the data for M. tuberculosis are more equivocal than for the other speci

46 Case fatality ratios in children with tuberculosis are poorly understood-particularly those am

47 , pulmonary tuberculosis, and extrapulmonary tuberculosis are provided.

48 ng, preventive therapy, and surveillance for tuberculosis are underused interventions in contacts, pa

49 greatest reductions were noted for polio and tuberculosis at -3594 (95% CI -4811 to -2377; p<0.0001)

50 vince, South Africa, with a diagnosis of XDR tuberculosis between 2011 and 2014.

51 sociated with low-level BDQ resistance in M. tuberculosis Both genes encode transcriptional regulator

52 (Meles meles) naturally infected with bovine tuberculosis (bTB) at Woodchester Park in Gloucestershir

53 ecognised as a wildlife reservoir for bovine tuberculosis (bTB); the control of which is complex, cos

54 er States in 2014 to achieve a world free of tuberculosis by 2035, we call on all tuberculosis stakeh

55 host immune responses against Mycobacterium tuberculosis by harnessing the SET8-NQO1/TRXR1 axis with

56 Many South Africans diagnosed with RR-tuberculosis by Xpert initiate a suboptimal regimen, wit

57 untries move towards detecting the 3 million tuberculosis cases estimated to be missed annually, and

58 Of 12 culture-confirmed pulmonary tuberculosis cases identified among children with >/=2 I

59 ders to act to accurately diagnose and treat tuberculosis caused by M bovis in human beings.

60 For example, tuberculosis, caused by the bacterial pathogen Mycobacte

61 Mycobacterium tuberculosis causes pulmonary tuberculosis (TB) and clai

62 e Red staining) to interrogate Mycobacterium tuberculosis cell state.

63 and initiate oxidative damage should improve tuberculosis chemotherapies.

64 Tuberculosis chemotherapy is dependent on the use of the

65 Aug 12, 2016, that included terms related to tuberculosis, children, mortality, and population repres

66 t it will be a call to action for the global tuberculosis community to make a sustained commitment to

67 ing Xpert as the initial diagnostic test for tuberculosis, compared with sputum smear microscopy (the

68 s previously confirmed to be positive for M. tuberculosis complex (MTBC) by qPCR.

69 Sputum from patients with tuberculosis contains subpopulations of metabolically ac

70 Mycobacterium tuberculosis continues to cause devastating levels of mo

71 ay be useful for taking timely decisions for tuberculosis control.

72 eficiency virus type 1 (HIV-1) infection and tuberculosis coprevalence.

73 nctions, including the production of anti-M. tuberculosis cytokines and inhibition of intracellular m

74 e than 96% (230 000, 185 000-289 000) of all tuberculosis deaths occurred in children not receiving t

75 Patients with tuberculosis diagnosed had significantly lower CD4 cell

76 o health care were identified as barriers to tuberculosis diagnosis and treatment uptake, whereas sup

77 Pooled sputum collection increased tuberculosis diagnosis by microscopy (odds ratio [OR] 1.

78 ill improve the efficiency and timeliness of tuberculosis diagnosis for patients in Pakistan.

79 the effects of sputum collection methods on tuberculosis diagnosis.

80 lly, just under half of patients encountered tuberculosis diagnostic and treatment capacity where the

81 roduction improved the cost-effectiveness of tuberculosis diagnostics.

82 ency strongly predicted the risk of incident tuberculosis disease among HHCs of patients with tubercu

83 ression to estimate odds ratios for incident tuberculosis disease by vitamin A and carotenoids levels

84 th baseline blood samples, 192 had secondary tuberculosis disease during follow-up.

85 ts were followed with prevalence surveys for tuberculosis disease for 6 years.

86 and determined risk of progression to active tuberculosis disease over the subsequent 6-24 months.

87 ) may develop symptoms and signs of disease (tuberculosis disease) or may have no clinical evidence o

88 etects rifampicin-resistant tuberculosis (RR-tuberculosis), enabling physicians to rapidly initiate a

89 XDR tuberculosis has evolved in several tuberculosis-endemic countries to drug-incurable or prog

90 though the vast majority of individuals with tuberculosis engaged the public health system, just over

91 mechanism of host lipid catabolism by an M. tuberculosis enzyme, augmenting our current understandin

92 h increasing drug-resistance, drives the MDR tuberculosis epidemic in Shanghai, China.

93 transmission are driving the ongoing global tuberculosis epidemic, and there is a pressing need for

94 a dynamic Markov model to represent India's tuberculosis epidemic, including a probabilistic framewo

95 To stop the tuberculosis epidemic, it is critical that we interrupt

96 Further, we showed that M. tuberculosis ESAT-6 family protein EsxL, encoded by Rv11

97 in children with HIV receiving treatment for tuberculosis (especially without antiretroviral therapy)

98 N: Without adequate treatment, children with tuberculosis, especially those younger than 5 years, are

99 In summary, we demonstrate that M. tuberculosis EsxL inhibits antigen presentation by enhan

100 ase, contact, and household risk factors for tuberculosis from which to derive a score and classify c

101 ng to identify the target of a Mycobacterium tuberculosis growth inhibitor, pointed to a mechanism in

102 A rough M. tuberculosis H37Rv DeltapapA1 sulfoglycolipid-deficient

103 Although patients with isoniazid-resistant tuberculosis had a high cure rate, the cases of recurren

104 multidrug-resistance risk group if drugs for tuberculosis had been taken in the past 6 months, but dr

105 367 (5%) of 7982 patients with tuberculosis had MDR tuberculosis and 324 (88%) of these

106 tem, a quarter of all notified patients with tuberculosis had no bacteriological confirmation of dise

107 need for an effective vaccine against human tuberculosis has driven the development of different can

108 XDR tuberculosis has evolved in several tuberculosis-endemic

109 Mycobacterium tuberculosis has succeeded as a human pathogen for tens

110 des successful T cell-mediated control of M. tuberculosis have not been well defined.

111 rs, and some pathogens such as Mycobacterium tuberculosis have over 90 toxin-antitoxin operons.

112 therapy era, including the inability to cure tuberculosis, high mortality, and the need for alternati

113 tigens provides new insights into human anti-tuberculosis immunity.

114 alysis, the incidence of multidrug-resistant tuberculosis in 2024 would be 3.3 (95% uncertainty range

115 ert introduction for people investigated for tuberculosis in 40 primary health facilities (20 cluster

116 ed programmatic management of drug-resistant tuberculosis in 90 countries.

117 ampicin resistance in rifampicin-susceptible tuberculosis in a setting of high human immunodeficiency

118 We developed a score to predict risk of tuberculosis in adult contacts of tuberculosis index cas

119 i, Salmonella typhimurium, and Mycobacterium tuberculosis in human and mouse macrophages.

120 es allows rapid and specific detection of M. tuberculosis in live animals.

121 11 mutant is similar to that of wild-type M. tuberculosis in macrophages, the mutant exhibits impaire

122 There is no biomarker for diagnosing active tuberculosis in patients with human immunodeficiency vir

123 The 10-year risks of tuberculosis in the low-risk, medium-risk, and high-risk

124 tection group if no drugs had been taken for tuberculosis in the past 6 months or to the multidrug-re

125 ae, Legionella pneumophila, or Mycobacterium tuberculosis-in a case study to show how our map can be

126 s transmission and accelerate the decline in tuberculosis incidence and mortality.

127 Global tuberculosis incidence has declined marginally over the

128 to greater than 0.7 IU/ml had 10-fold higher tuberculosis incidence rates than those who maintained v

129 intracellular potency against Mycobacterium tuberculosis, including multidrug-resistant strains, and

130 ct risk of tuberculosis in adult contacts of tuberculosis index cases.

131 2 can significantly reduce the Mycobacterium tuberculosis-induced bioactive IL-1beta production.

132 M. tuberculosis-infected IL-21R KO mice had enhanced bacter

133 Mycobacterium tuberculosis-infected macrophages and dendritic cells ar

134 g-specific T cells in lungs compared with M. tuberculosis-infected WT mice.

135 The tests for diagnosing latent tuberculosis infection (LTBI) are limited by a poor pred

136 have no clinical evidence of disease (latent tuberculosis infection [LTBI]).

137 ved that exosomes released during a mouse M. tuberculosis infection contribute significantly to its T

138 bacterial persisters, and rapidly cleared M. tuberculosis infection in vivo.

139 Accurate estimates of Mycobacterium tuberculosis infection in young children provide a criti

140 ially in settings where the prevalence of M. tuberculosis infection is low and environmental sensitiz

141 critical cellular source of IL-10 during M. tuberculosis infection is still unknown.

142 erated during host immune responses after M. tuberculosis infection of macrophages.

143 fungal diseases into existing HIV infection, tuberculosis infection, diabetes, chronic respiratory di

144 Furthermore, during M. tuberculosis infection, Il10 expression in CD4(+) T cell

145 ndations about diagnostic testing for latent tuberculosis infection, pulmonary tuberculosis, and extr

146 After M. tuberculosis infection, TOLLIP-deficient monocytes demon

147 robust T cell response observed during an M. tuberculosis infection.

148 ated with increased susceptibility to latent tuberculosis infection.

149 ve autophagy of Mtb and host defense against tuberculosis infection.

150 variability in the response to Mycobacterium tuberculosis infection.

151 rotection in a murine model of Mycobacterium tuberculosis infection.

152 Tuberculosis is an ancient human disease, estimated to h

153 The transmission of tuberculosis is complex.

154 amma target genes required for control of M. tuberculosis is inducible NO synthase (iNOS).

155 Mycobacterium tuberculosis is known to modulate the host immune respon

156 Although isoniazid-resistant tuberculosis is more common than multidrug-resistant tub

157 Mycobacterium tuberculosis is recognised as the primary cause of human

158 Genomic sequences of M. tuberculosis isolates displayed significant variations i

159 sequenced and analyzed the genomes of 138 M. tuberculosis isolates from 97 patients sampled between 2

160 A set of 296, mostly XDR, clinical M. tuberculosis isolates from four countries were subjected

161 osis is more common than multidrug-resistant tuberculosis, it has been much less studied.

162 by ambient conditions and crowding and by M. tuberculosis itself.

163 als have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly

164 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year.

165 gmenting our current understanding of how M. tuberculosis meets its nutrient requirements under hypox

166 er analysis may provide new insights into M. tuberculosis metabolic processes and new targets for dru

167 the biosynthesis of biotin in Mycobacterium tuberculosis (Mtb) and is an essential enzyme for bacter

168 Mycobacterium tuberculosis (Mtb) can persist in the human host in a la

169 Mycobacterium tuberculosis (Mtb) expresses a broad-spectrum beta-lacta

170 as evaluated for inhibition of Mycobacterium tuberculosis (Mtb) growth and Mtb Antigen 85C (Mtb Ag85C

171 These may restrict Mycobacterium tuberculosis (Mtb) growth, or progress to central necros

172 ow host genetic factors affect Mycobacterium tuberculosis (Mtb) infection outcomes remains largely un

173 pressed at different stages of Mycobacterium tuberculosis (Mtb) infection, in particular early secret

174 ndicate that the metabolism of Mycobacterium tuberculosis (Mtb) inside its host cell is heavily depen

175 Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosi

176 303 randomly selected clinical Mycobacterium tuberculosis (MTB) isolates from 303 patients (collected

177 Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of dis

178 Ribosomes from Mycobacterium tuberculosis (Mtb) possess species-specific ribosomal RN

179 During human infection, Mycobacterium tuberculosis (Mtb) survives the normally bacteriocidal p

180 epressor of EthA expression in Mycobacterium tuberculosis (Mtb) that reduces the efficacy of ethionam

181 ost macrophage apoptosis is essential for M. tuberculosis (Mtb) to replicate intracellularly while pr

182 utophagy of the human pathogen Mycobacterium tuberculosis (Mtb).

183 n implicated in persistence of Mycobacterium tuberculosis (Mtb).

184 The experimental regimens kill M. tuberculosis much more rapidly than the standard regimen

185 urrogate model, suggests the existence of M. tuberculosis mutator strains.

186 ed associations of these immune markers with tuberculosis mycobacteremia.

187 Among asymptomatic contacts, incident tuberculosis occurred in six (<1%) of 795 contacts infec

188 basis of all granulomatous diseases, such as tuberculosis or sarcoidosis, and is decisive for disease

189 view committee), pulmonary or extrapulmonary tuberculosis, or any bacterial infectious disorder of gr

190 can patients with extensively drug-resistant tuberculosis, or resistance beyond extensively drug-resi

191 (household wealth) quintile for HIV/AIDS and tuberculosis, other communicable diseases (excluding HIV

192 Many M. tuberculosis P450s remain uncharacterized, suggesting th

193 c mycobacterial physiology and Mycobacterium tuberculosis pathogenesis.

194 which are critically important aspects of M. tuberculosis pathogenicity.

195 n vitro, and autologous MSCs transfused into tuberculosis patients have been found to be safe and imp

196 ens associated with serological responses in tuberculosis patients.

197 In contrast, M. tuberculosis populations subject to less drug pressure s

198 nd resistance determinants within endemic M. tuberculosis populations.

199 different proposed methods of estimating M. tuberculosis prevalence, including a method described by

200 ensified case finding and increase uptake of tuberculosis preventive therapy.

201 ously uncharacterized membrane-associated M. tuberculosis protein encoded by Rv2672 is conserved excl

202 llent substrate for accurate detection of M. tuberculosis rapidly and specifically in animals, facili

203 imates were derived from national electronic tuberculosis register data, laboratory data, and publish

204 We obtained patient data from the California Tuberculosis Registry and calculated traffic volumes and

205 Tuberculosis relapse is a barrier to shorter treatment.

206 tributed 87% of acquired multidrug-resistant tuberculosis, related to irregular adherence; the remain

207 During the study period, 469 patients (18 tuberculosis-related acute respiratory distress syndrome

208 We defined tuberculosis-related catastrophic costs as the sum of di

209 Tuberculosis remains a global health problem with an eno

210 Tuberculosis (TB) due to Mycobacterium tuberculosis remains a major global infectious disease p

211 Tuberculosis remains one of the deadliest infectious dis

212 eclined marginally over the past decade, and tuberculosis remains out of control in several parts of

213 I), pulmonary (PTB) or extrapulmonary (EPTB) tuberculosis remains unclear.

214 es became necrotic, providing a niche for M. tuberculosis replication before escaping into the extrac

215 evant to understanding the environment of M. tuberculosis replication in the host.

216 nase, is a virulence factor in Mycobacterium tuberculosis, required for inhibition of phagolysosomal

217 used by the bacterial pathogen Mycobacterium tuberculosis, requires months of antibiotic therapy even

218 ng the relationships between the detected M. tuberculosis resistance mutations and M/XDR-TB treatment

219 rmine if there was an association between M. tuberculosis resistance mutations and patient mortality.

220 MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (RR-tuberculosis), enabling physicians to r

221 eus, Streptococcus pneumoniae, Mycobacterium tuberculosis, Salmonella enterica, Klebsiella pneumoniae

222 mmes should consider point-of-care CRP-based tuberculosis screening to improve the efficiency of inte

223 review and meta-analysis of global zoonotic tuberculosis showed that the same challenges and concern

224 cy, phenotype, and functional capacity of M. tuberculosis-specific CD4 T cells in HIV-infected and HI

225 ing to impaired proliferative capacity of M. tuberculosis-specific CD4 T cells in HIV-infected indivi

226 The ex vivo proliferative capacity of M. tuberculosis-specific CD4 T cells was markedly impaired

227 wer total frequency of cytokine-producing M. tuberculosis-specific CD4 T cells, and preferential depl

228 here is extensive depletion of Mycobacterium tuberculosis-specific CD4+ T cells in blood during early

229 rential depletion of a discrete subset of M. tuberculosis-specific IFN-gamma(+)IL-2(-)TNF-alpha(+) CD

230 nt or active TB (aTB), were screened using M.tuberculosis-specific MHC class II tetramers.

231 f the cell surface trehalose mycolates of M. tuberculosis specifically generates metabolic intermedia

232 free of tuberculosis by 2035, we call on all tuberculosis stakeholders to act to accurately diagnose

233 INTERPRETATION: Recent transmission of MDR tuberculosis strains, with increasing drug-resistance, d

234 t, endemic diseases, such as HIV in 2017 and tuberculosis, struggle to maintain the same attention.

235 Mycobacterium tuberculosis' success as a pathogen comes from its abili

236 r conditional depletion of wag31 impacted M. tuberculosis susceptibility to this compound.

237 Mycobacterium tuberculosis causes pulmonary tuberculosis (TB) and claims 1.8 million human lives pe

238 ted individuals remain highly susceptible to tuberculosis (TB) and have an enrichment of oral anaerob

239 t the highest risk for progressing to active tuberculosis (TB) and have various sensitivities and spe

240 ctive tools to monitor the long treatment of tuberculosis (TB) are lacking.

241 New non-sputum biomarker tests for active tuberculosis (TB) diagnostics are of the highest priorit

242 , lansoprazole can treat or prevent incident tuberculosis (TB) disease.

243 Tuberculosis (TB) due to Mycobacterium tuberculosis rema

244 The Singapore Tuberculosis (TB) Elimination Program (STEP) was set up

245 Eradication of systemic tuberculosis (TB) has been limited by neglected populati

246 After steady decline since the 1990s, tuberculosis (TB) incidence in New York City (NYC) and t

247 Tuberculosis (TB) is a paramount example of a chronic in

248 Bovine tuberculosis (TB) is a zoonotic disease caused by Mycoba

249 Tuberculosis (TB) is an important and widespread disease

250 Tuberculosis (TB) is responsible for enormous global mor

251 development of an effective vaccine against tuberculosis (TB) is that the attributes of protective C

252 re-associated BCG infection in the Barcelona tuberculosis (TB) program were reviewed from 1 January 2

253 Worldwide, tuberculosis (TB) remains one of the most prevalent infe

254 Comorbid diabetes mellitus (DM) increases tuberculosis (TB) risk and adverse outcomes but the path

255 Tuberculosis (TB) treatment is long and complex, typical

256 RATIONALE: Administration of tuberculosis (TB) vaccines in participants with previous

257 r individuals with multidrug-resistant (MDR) tuberculosis (TB).

258 omplex lung lesions that are the hallmark of tuberculosis (TB).

259 cause devastating levels of mortality due to tuberculosis (TB).

260 in many common infectious diseases, such as Tuberculosis (TB).

261 the cytochrome P450 enzyme in Mycobacterium tuberculosis that catalyzes a single intramolecular C-C

262 Mycobacterium tuberculosis that was FDA microscopy negative was parado

263 quency throughout the day and in response to tuberculosis therapy.

264 ent dosing schedules in first-line pulmonary tuberculosis therapy.

265 ntage of XDR tuberculosis among incident MDR tuberculosis to increase, reaching 8.9% (95% prediction

266 drug-incurable or programmatically incurable tuberculosis (totally drug-resistant tuberculosis).

267 ions that target these events will interrupt tuberculosis transmission and accelerate the decline in

268 High rates of tuberculosis transmission are driving the ongoing global

269 n about tuberculosis transmission, using the tuberculosis transmission cascade as a framework, and to

270 A simple cascade for tuberculosis transmission has been proposed in which (1)

271 her, the interventions required to interrupt tuberculosis transmission must be targeted to high-risk

272 community to make a sustained commitment to tuberculosis transmission science.

273 a high-level overview of what is known about tuberculosis transmission, using the tuberculosis transm

274 s epidemic, it is critical that we interrupt tuberculosis transmission.

275 is series, which address specific aspects of tuberculosis transmission.

276 Cough is the major determinant of tuberculosis transmission.

277 lus at 2 months with subsequent unsuccessful tuberculosis treatment outcome (failure/death during tre

278 on.The antibiotic pyrazinamide is central to tuberculosis treatment regimens, globally.

279 Tuberculosis treatment was associated with VF (SHR, 11.5

280 analyses by whether or not children received tuberculosis treatment, age (0-4 years, 5-14 years), and

281 Fifteen (15.3%) did not start tuberculosis treatment, mostly owing to rapidly deterior

282 children with HIV and children not receiving tuberculosis treatment.

283 is deaths occurred in children not receiving tuberculosis treatment.

284 sing host-directed therapeutic adjuvants for tuberculosis treatment.

285 ing the cytochrome bc1 :aa3 in Mycobacterium tuberculosis triggered interest in the terminal respirat

286 e reasons, highlighting a major challenge in tuberculosis vaccine design.

287 Tuberculosis was diagnosed during follow-up in 6.4% (13/

288 ldtype allele of wag31 in APYS1-resistant M. tuberculosis was dominant and restored susceptibility to

289 CASE REPORT: A young woman with pulmonary tuberculosis was found to have disseminated tuberculosis

290 hereby HIV impairs protective immunity to M. tuberculosis, we evaluated the frequency, phenotype, and

291 in-sensitive, previously untreated pulmonary tuberculosis were randomly assigned in a 1:1:1:1:2 ratio

292 resistance beyond extensively drug-resistant tuberculosis, were followed up over a period of 6 years.

293 raction directly from patient samples for M. tuberculosis WGS.

294 M. tuberculosis WhiB1 is a NO-responsive Wbl protein (actin

295 tuberculosis (Mtb) is the causative agent of tuberculosis, which kills 1.8 million annually.

296 wnstream cases of extensively drug-resistant tuberculosis with almost identical sequencing profiles s

297 opathology suggested localized hepatobiliary tuberculosis with features of secondary sclerosing chola

298 abolically active and inactive Mycobacterium tuberculosis with unknown implications for infectiousnes

299 00) children younger than 15 years died from tuberculosis worldwide in 2015; 80% (191 000, 95% UI 132

300 is recognised as the primary cause of human tuberculosis worldwide.